Kempenhaeghe

Running trials

• Recruiting

  Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach

  2023-507843-12-01· Phase 3· Source

• Recruiting

  REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

  NCT06922175· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Recruiting

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

  NCT05716100· Phase 3· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy6 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

  NCT04940624· Phase 3· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· Source

Trial sites

• Kempenhaeghe8 trials
• Kempenhaeghe - Academisch Centrum voor Epilepsie1 trial
• Kempenhaeghe - PPDS3 trials